Acupuncture for Chemotherapy-induced Peripheral Neuropathy (NCT01892852) | Clinical Trial Compass
UnknownNot Applicable
Acupuncture for Chemotherapy-induced Peripheral Neuropathy
South Korea36 participantsStarted 2013-06
Plain-language summary
The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma.
* Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta and/or Lyrica. Patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period.
* Patients, or the legal guardians of patients, must have the ability to understand Korean, and be ble to provide informed consent.
* ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2.
* If the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception.
Exclusion Criteria:
* Other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and HIV.
* Current active treatment for lymphoma or multiple myeloma
* Ongoing local infection at or near the acupuncture point adopted in this trial.
* Severe immunocompromised patients, leukopenia ( \< 4,000/㎣) or neutropenia ( \< 1,500/㎣)
* Known coagulopathy, thrombocytopenia (\< 50,000/㎣), and taking heparin (including low molecular weight heparin) or Coumadin at any dose.
* Serious emotional or mental problems that precludes study entry.
* Mental and physical disability that precludes accur…
What they're measuring
1
Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline
Timeframe: At baseline, 1, 2, 3, and 7 wks from baseline